Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name ranibizumab. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
Figure 1 Anti-Human VEGF Antibody Fab Fragment (TP-104CL) in WB
Western blot analysis of TP-104CL was performed with Recombinant Human VEGF protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TP-104CL and HRP Goat Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.
Figure 2 Anti-Human VEGF Antibody Fab Fragment (TP-104CL) in ELISA
ELISA analysis of TP-104CL was performed by coating with Recombinant Human VEGF Protein. Then blocked with BSA, and incubated with Anti-VEGF Therapeutic Antibody (ranibizumab) (TP-104CL). The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Ranibizumab.
For Research Use Only. Not For Clinical Use.